FinTok
developed by Fiadm s.r.o. · future of webapps
Ostatné · BSX
nákup
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 0,76 | 0,58–0,84 | 0,75 | +1,5 % |
| budúci štvrťrok | 0,84 | 0,82–0,91 | 0,80 | +4,6 % |
| tento rok | 3,26 | 3,16–3,37 | 3,06 | +6,7 % |
| budúci rok | 3,41 | 3,19–3,90 | 3,26 | +4,5 % |
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 5,1 mld. | 5,1 mld. | +1,2 % |
| budúci štvrťrok | 5,4 mld. | 5,3 mld. | +2,3 % |
| tento rok | 21,2 mld. | 20,1 mld. | +5,6 % |
| budúci rok | 22,2 mld. | 21,2 mld. | +4,9 % |
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| O'connor Padraig AndrewOfficer | iná transakcia | – | 02.09. |
| Morano Susan E.Director | nákup | 100 408 | 25.08. |
| Habiger David CDirector | nákup | 99 937 | 05.08. |
| Habiger David CDirector | nákup | 56 887 | 04.08. |
| Mahoney Michael FChief Executive Officer | nákup | 9,0 mil. | 03.08. |
| Ludwig Edward J.Director | nákup | 227 400 | 31.07. |
| Monson Jonathan RChief Financial Officer | iná transakcia | – | 01.07. |
| Mahoney Michael FChief Executive Officer | dar akcií | – | 28.05. |
| Ludwig Edward J.Director | nákup | 202 914 | 20.05. |
| Habiger David CDirector | nákup | 251 098 | 20.05. |
| Pegus CherylDirector | nákup | 99 987 | 20.05. |
| Ludwig Edward J.Director | odmena v akciách | – | 07.05. |
Blackrock Inc.8,95 %
Vanguard Capital Management LLC6,70 %
State Street Corporation4,84 %
Primecap Management Company3,49 %
FMR, LLC3,15 %
Geode Capital Management, LLC2,31 %
Vanguard Portfolio Management LLC2,06 %
Shaw D.E. & Co., Inc.1,76 %
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
K tomuto aktívu zatiaľ nemáme odporúčanie.
Žiadne predikcie.
Analytická spoločnosť Bernstein znížila cieľovú cenu pre akcie Boston Scientific. Dôvodom je konkurencia v oblasti medicínskych zariadení. Toto zníženie môže signalizovať zvýšený tlak na marže spoločnosti a ovplyvniť investorov.
